Anti-obesity drugs are only part of the larger treatment plan for most patients. Exercise and nutrition are also keys.

Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema fell short of some ...

Obesity is a major global health issue, increasing the risk of heart disease, diabetes, and high blood pressure. Despite many ...

Anyone who has tried to lose weight by cutting calories knows the frustration—after initial success, weight loss slows down ...

Obesity has long been classified as a global epidemic — and new data published in The Lancet journal spotlights how much ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

A team of researchers have made a groundbreaking development related to a protein that is naturally produced in the body but ...

A new screening intervention in the primary care setting can improve the identification and management of obesity risk in pediatric patients, according to a poster presented at the National ...

It was the second disappointing large study for CagriSema, after a trial in people with obesity but no history of diabetes fell short of expectations in December. Novo is counting on the new shot ...